These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1065 related items for PubMed ID: 15888152

  • 1. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 2. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
    [Abstract] [Full Text] [Related]

  • 3. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
    Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A.
    Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
    [Abstract] [Full Text] [Related]

  • 4. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
    Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A.
    J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
    [Abstract] [Full Text] [Related]

  • 5. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 7. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
    Reich K, Nestle FO, Wu Y, Bala M, Eisenberg D, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Eur J Dermatol; 2007 Apr; 17(5):381-6. PubMed ID: 17673380
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
    Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.
    Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
    [Abstract] [Full Text] [Related]

  • 9. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD.
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [Abstract] [Full Text] [Related]

  • 10. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators.
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [Abstract] [Full Text] [Related]

  • 11. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N, Begon E, Lebbé C, Lioté F, Lahfa M, Bengoufa D, Morel P, Dubertret L, Bachelez H.
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [Abstract] [Full Text] [Related]

  • 12. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
    Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.
    J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
    [Abstract] [Full Text] [Related]

  • 13. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Aug; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 15. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A, Tan E, Ilchyshyn A, Berth-Jones J.
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [Abstract] [Full Text] [Related]

  • 16. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 17. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 18. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Jan; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 20. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.